XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death
Non-metastatic Castrate Resistant prostate cancer patients take note. The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone. It will be a [...]